The MIRASOL trial (NCT04209855) in particular firmly demonstrated the efficacy of MIRV versus chemotherapy in patients with high-grade serous PROC, with an ORR of 42.3% and overall survival of 16 months.98 As a result, MIRV received accelerated approval from the US Food and Drug Administration in 2022 for the treatment of adults with FRα-positive ovarian, fallopian tube, or primary peritoneal, cancers, after failure of at least one standard treatment regimen99 (Table 2). The gene discussed is FOLR1; the disease is cancer.